ClinicalTrials.gg
CompletedNCT02583464Updated Oct 22, 2015

Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.

A Phase 1 interventional study of Tenofovir disoproxil fumarate and emtricitabine in Acquired Immunodeficiency Syndrome, sponsored by Laboratorio Elea Phoenix S.A.. Completed at 1 site in Argentina. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-22.

Sponsored by Laboratorio Elea Phoenix S.A. · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing tenofovir in Acquired Immunodeficiency Syndrome — 3 open to participants now, 3 under way, 1 of them phase 3. Tenofovir · Acquired Immunodeficiency Syndrome.

Enrollment
24th of 33
24 · median 52
Started
2014
with 2 others
Phase 1
4 of 33
none open now
Registered
17th of 33
by date

Among the 33 studies testing tenofovir in Acquired Immunodeficiency Syndrome, this one is the 24th largest by enrollment, is one of 3 that started in 2014, is one of 4 in phase 1, and was the 17th registered.

Acquired Immunodeficiency Syndrome

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

3 of the 33 studies testing tenofovir in Acquired Immunodeficiency Syndrome are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing tenofovir in Acquired Immunodeficiency Syndrome, or all of them as a file.
02

Study summary

Objective: To evaluate the relative bioavailability of a new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) and compare this formulation with the branded formulation (R) to meet regulatory criteria for marketing the test product in Argentina.

Read the detailed description

A randomized-sequence, open-label, two-period crossover study was conducted on 24 healthy Caucasian volunteers in a fasting state. A single oral dose of either T or R formulations was followed by a 7-day washout period. Blood samples were collected at baseline and 0.25, 0.50, 0.75, 1, 1.25, 1.5 2, 2.5, 3, 4, 7, 12, 24 and 48 h after administration. Emtricitabine and tenofovir concentrations were determined using a validated LC (liquid chromatography) - MS (mass spectrometry) / MS method. Adverse events were monitored based on clinical parameters and volunteer reports.

03

Conditions studied

  • Acquired Immunodeficiency Syndrome
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects of both sexes between 21 and 55 years.
  2. Subjects with (BMI) between 19 and 27 kg / m².
  3. Subjects whose complementary tests (, blood and urine) are within normal and / or clinically insignificant according to the judgment of the investigator. Women of childbearing age should have a negative pregnancy test and use a reliable method of during the study (IUD or condoms)
  4. Subjects with systolic blood pressure between 110 mmHg and 139 mmHg; diastolic pressure between 70 mmHg and 89 mmHg; heart rate between 50 and 90 beats per minute.
  5. Subjects who signed .

Exclusion criteria

Exclusion Criteria:

  1. Background of allergies (except untreated asymptomatic seasonal allergies), drug and / or hypersensitivity to any component of the formulations studied.
  2. Drop of more than 20 mmHg in systolic blood pressure or more than 10 mmHg diastolic pressure in the first 3 minutes of postural change.
  3. Active smoker more than 10 cigarettes / day.
  4. Pregnant or lactating women.
  5. Current clinical evidence of severe digestive disorders, surgery of the digestive tract (except appendectomy).
  6. Current clinical evidence of kidney disease.
  7. Current evidence of liver disorders
  8. Current clinical evidence of respiratory and heart diseases.
  9. The presence of diabetes mellitus, thyroid dysfunction or other endocrine disorder.
  10. Evidence of gastroduodenal disease.
  11. Current presence of any .
  12. History of abuse or addiction to drugs or alcohol during the past three years.
  13. Participation in a clinical trial within the last three months.
  14. Use of any drug within fourteen days before the start of the study.
  15. Subject donated or suffered blood loss during the last twelve weeks before the start of the study, or intends to donate blood within three months of the completion of the study.
  16. Excessive drinking of tea, cocoa, mate, coffee and / or beverages containing caffeine (> 5 cups / day) or wine (> 0.5 L / day) or alcohol (> 50 ml / day).
  17. abnormalities.
  18. Positive serology for , or .
  19. Women who are not using effective (IUD, condom)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Test-Reference

    A new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).

    Drug: Tenofovir disoproxil fumarate and emtricitabine

  • Experimental
    Reference-Test

    A branded formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (R) followed by a new formulation (T).

    Drug: Tenofovir disoproxil fumarate and emtricitabine

Interventions

  • DrugTenofovir disoproxil fumarate and emtricitabine

    Drug pages: Tenofovir · Emtricitabine

    Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration [Cmax]

    Time frame: 48 hours

  2. Area Under the Curve [AUC]

    Time frame: 48 hours

Secondary outcomes

  1. Adverse events

    Time frame: 48 hours

07

Study locations

1 site
  • Laboratorio Elea SACIFyA
    Capital Federal, Buenos Aires C1417AZE, Argentina
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2015
First posted
Oct 22, 2015
Start
Sep 2014
Primary completionActual
Oct 2014
CompletionActual
Dec 2014
Last update
Oct 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02583464
Lead sponsor
Laboratorio Elea Phoenix S.A.
Responsible party
Sponsor
First posted
Oct 22, 2015
Start date
Sep 2014
Primary completion
Oct 2014
Completion
Dec 2014
Last update
Oct 22, 2015

Study contacts

Guillermo Di Girolamo, MD
principal investigator · Centro de la Asociación Mutual de Profesionales del Hospital Italiano

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tenofovir · Emtricitabine

Start the discussion